Event > Conference >
MPS World Summit Berlin 2023
After a very successful inaugural conference in New Orleans, the MPS World Summit is in Europe. Organized by the Johns Hopkins Center for Alternatives to Animal Testing (CAAT) and EUROoCS, with the support of more than forty organizations, is proud to present the Microphysiological Systems World Summit.
Head to our exhibition stand – #7
Our dedicated team of creative problem solvers will be available to answer questions and share over a decade of organ-on-a-chip (OOC) expertise with you!
We look forward to meeting you to discuss how our PhysioMimix® range of products and services can help to improve the predictivity of your toxicology workflows and address your current workflow limitations – such as modelling the immune system in vitro and testing the safety of new modality drugs with human-specific modes of action.
Get familiar with our human-relevant single- and multi-organ in vitro models and learn more about their proven track record for delivering clinically translatable results, plus meet the new game-changing product in our PhysioMimix OOC range of microphysiological systems!
Organ-on-a-chip Workshop
How to build robust predictive human organ models to improve the success of novel therapies discovery
Despite billions in annual investment, most drugs never reach the market because preclinical experiments fail to predict human effects. Building more predictive, human-relevant models is key to reducing drug attrition rates. In this training session, provided by CN Bio, we will explore how our PhysioMimix® MPS technology can be implemented in your research to create human-specific tissue models such as liver, gut, or lung models to generate clinically translatable data. MPSs extend culture longevity up to a month, enabling studies that were not previously possible, such as the ability to profile phase I and II drug metabolism, characterize slowly metabolized compounds, identify potential metabolite-driven toxicity, or detect chronic and idiosyncratic toxicity.
The trainees will learn:
- The current limitations of the standard preclinical toolbox and the need for more human-relevant alternatives
- The regulatory landscape and the need for standardization (FDA modernization act)
- Overview of specific applications and their associated organotypic tissue models (e.g., disease modeling, drug efficacy and drug toxicity)
- The crucial need for cell validation and quality control assays as well as clinically translatable endpoints
Date: Monday, June 26, 2023
Time: 1:00 – 4:30 PM CEST
Room: Salon 21
Presentation from: Dr Atefeh Mobasseri & Dr Audrey Dubourg, CN Bio
Podium presentations
A PK/PD translational microphysiological system to explore anti-cancer therapies efficacy on 3D tumour spheroids and patient derived organoids
Our MPS platform is able to mimic animal and human PK profiles thus potentially avoiding many failures of novel therapies which are due to a missing physiologically relevant link between preclinical and clinical data. By tailoring individualized PK profiles and therapeutic schedules, we introduce a valuable tool and strategy in the pursuit of personalized medicine for the treatment of cancer.
Date: Wednesday, June 28, 2023
Time: 11:30-12:00
Session: 4.5 MPS & Cancer Session
Room: Hall Berlin A
Presentation from: Dr Tudor Petreus, CN Bio
Communication is key: exploring local and systemic inflammatory responses to infection using a multi-organ lung-liver-immune axis microphysiological system
The coronavirus disease 2019 (Covid-19) pandemic had an immense impact on human health and the economy1 and presented an immediate need to understand the biology of SARS-CoV-2 virus and identify effective therapeutics against the disease. Despite a successful vaccine roll-out, the threat of SARS-CoV-2 to human health is still present and better models to study the disease are needed. Traditional in vitro immortalised cell culture models are unable to effectively replicate complex tissues and human physiological environments2 and alternatives such as animal models, are expensive and have fundamental differences to the human host which prevent direct comparisons to be made. This is particularly evident for SARS-CoV-2, as viral adaptations may have allowed more effective infection in humans compared to rodents3. Dynamic microphysiological systems have the potential to bridge the knowledge gap between traditional in vitro models and human clinical trials to enable us to understand SARS-CoV-2 infection and identify effective therapeutics.
We have therefore undertaken experiments to compare a ‘dynamic’ lung-on-a-chip system (CN-Bio’s PhysioMimix™) to ‘static’ primary lung cells grown without an MPS. We will present data which shows significant differences between viral recovery and replication rates in static vs dynamic lung models. We have also been able to compare upper and lower airway infection of multiple SARS-CoV-2 variants in an MPS system and will present live viral recovery rates, qPCR and gene expression data which demonstrates infectivity differences between the upper and lower lung airway when exposed to SARS-CoV-2 variants. These data will be discussed within the clinical context of the pathology and transmission of SARS-CoV-2.
Date: Tuesday, June 27, 2023
Time: 15:20-15:40
Room: Salon 21
Presentation from: Dr Emily Richardson, CN Bio
Customer podium presentations
3D Liver-on-Chip with a perfusable physiologic-like vascular channel
Date: Tuesday, June 27, 2023
Time: 13:00-15:20
Room: Hall Berlin D-E
Presentation from: Erika Ferrari, Roberta Visone, Paola Occehetta, Linda Griffith, Marco Rasponi
(Politencnico di Milano, BiomimX & MIT)
3D Liver-on-Chip with a perfusable physiologic-like vascular channel
Date: Tuesday, June 27, 2023
Time: 13:00-15:20
Room: Hall Berlin D-E
Presentation from: Erika Ferrari, Roberta Visone, Paola Occehetta, Linda Griffith, Marco Rasponi
(Politencnico di Milano, BiomimX & MIT)
DigiLoCS – A digital liver-on-chip simulator for predicting human metabolism of drugs
Date: Tuesday, June 27, 2023
Time: 13:00-15:20
Room: Hall Berlin D-E
Presentation from: Christian Maass & Stephan Schaller
Session: 2.4 Applications in drug development – Safety
CN Bio posters
Connecting the human intestine and liver: a primary jejunum and primary hepatocyte multi-organ MPS for more predictive studies of human drug ADME and oral bioavailability
Poster Board: 95
Abstract ID: 364
Poster Session: Wednesday, June 28, 2023
Presentation from: CN Bio & Altis
Time: 10:00 – 11:30
Bridging the gap – how human microphysiological systems improve the translatability of NASH Drug Discovery
Poster Board: 30
Abstract ID: 278
Poster Session: Wednesday, June 28, 2023
Presentation from: Raul Silva, CN Bio
Time: 14:30 – 16:00
Customer posters citing the use of PhysioMimix OOC
Comparison of commercial NASH models as tools for pharmaceutical research and development
Poster: 121
Presentation from: Bayer, Germany
Poster session: Tuesday, June 27, 2023
Time: 09:00 – 10:30
Immune-competent gut MPS for host-microbe-immune interaction
Poster: 28
Presentation from: University of Amsterdam, MIT, John Hopkins University & Harvard Medical School
Poster session: Tuesday, June 27, 2023
Time: 15:30 – 17:00
A Novel Microfluidic Liver-on-chip model: Application in regulated Genotoxicity testing
Poster: 108
Presentation from: Charles River, Canada
Poster session: Tuesday, June 27, 2023
Time: 10:00 – 11:30
A quantitative modeling workflow for the design, analysis, and interpretation of experimental studies in gut-liver organ-on-a-chip systems
Poster: 154
Presentation from: Bayer, Germany
Poster session: Tuesday, June 27, 2023
Time: 15:30 – 17:00
Using a complex NASH in vitro model for drug development with siRNA technologies
Poster: 272
Presentation from: Novo Nordisk, Denmark
Poster session: Wesnesday, June 28, 2023
Time: 14:30 – 16:00
SARS-CoV-2 variant infection differences between static and microphysiological system models of the human lung
Poster: 614
Presentation from: Liverpool School of Tropical Medicine & CN Bio
Poster session: Thursday, June 29, 2023
Time: 10:30 – 11:30
Microphysiological Systems (MPS) Models of Endometriosis and Adenomyosis
Poster: 745
Presentation from: MIT, Oxford University, Wellcome Sanger Institute, Newton-Wellesley Hospital & Tufts University
Poster session: Thursday, June 29, 2023
Time: 10:30 – 11:30
Metabolic and proteomic profiling of Organophosphate Chemical Warfare Agent Exposure on CN Bio Human Liver-on-a-chip
Poster: 499
Presentation from: US Army
Poster session: Thursday, June 29, 2023
Time: 14:30 – 16:00
Our Team at MPS
Paul
Dr Paul Brooks is CEO at CN Bio, having joined in 2022. He has over 25 years of experience in building businesses and leading high-performance research, product, marketing, and sales teams to develop and commercialize new biotechnology technologies globally for drug discovery, bioproduction and diagnostics.
Dr Brooks has held senior leadership positions in the USA and the UK, including Head of Business Operations and Managing Director of Horizon Discovery Ltd; Chief Commercial Officer and Executive Board member of Oxford Genetics Ltd; Head of Discovery Research Services at MilliporeSigma (Merck KGaA); and Global Marketing Manager at Sigma-Aldrich Corp. Dr Brooks has a BSc in Biochemistry from the University of Wales, a PhD in Molecular Biology from the University of Manchester Institute of Science and Technology (UMIST), and an MBA from the University of Nottingham Business School.
Deepak
Deepak Singh joined CN Bio in February 2023, and we are excited that he will join us at another world-leading conference in just his second month. He has over 30 years of commercial experience within the life science industry. Deepak has been key in leading high-performance sales, support & marketing teams in establishing new technologies. Working with his teams, he has driven the global scalability of products & solutions into the markets in drug discovery, bioproduction, research and diagnostics. Deepak studied at the Polytechnic of Central London and gained a Bsc in Biotechnology.
Adrian
Dr Adrian Rea is a seasoned business developer with extensive commercial experience in the life science sector, Adrian joined CN-Bio Innovations as the European Director of Sales in June 2022. He brings valuable experience in the 3D cell culture market from his most recent role at InSphero, where he was responsible for developing business opportunities in European and Asian markets. He was previously Sales Director at Enzo Life Sciences, where he managed the restructuring of the global distributor sales channels and expanding the European sales operations. Adrian graduated from the University of Glasgow and received his PhD in pharmacology from Glasgow Caledonian University.
Audrey
Dr Audrey Dubourg is CN Bio’s Product Manager for the PhysioMimix® OOC range of microphysiological systems. Prior to joining CN Bio, she worked as a postdoctoral scholar at the University of California – Los Angeles (UCLA), in the US, in the Microbiology, Immunology and Molecular Genetics department. She completed an MSc in microbiology at the University of Montpellier II, followed by a PhD in microbiology/parasitology at the University of East Anglia. Audrey has extensive experience in the disciplines of molecular biology and 3D mammalian cell culture. Since joining CN Bio, she has been actively involved in promoting the benefits of incorporating organ-on-a-chip technology into drug discovery and development workflows.
Vaish
Vaishnavi Manoharan-Jayarajah is an Account Manager at CN Bio with 5+ years of experience handling key accounts within the Biopharma and research industries globally. Vaish has been with CN Bio for over 3 years with consultative sales experience with instruments and services. Prior to joining CN Bio, Vaish was an Education Associate and Lab Manager at STEMCELL Technologies. She graduated with a Biomedical Science degree and holds a Masters in Immunology from Imperial College London.
Atefeh
Dr Atefeh Mobasseri, Field Application Scientist at CN Bio, has an extensive background in tissue engineering and regenerative medicine. Before joining CN Bio, she gained a PhD in Biomedical materials from the University of Manchester and carried out postdoctoral roles at the University of Manchester and Kings College London investigating the interaction, and effect, of 3D scaffolds on cellular behaviour. Since joining CN Bio, she has been supporting their European customers in using CN Bio’s range of PhysioMimixTM systems to generate high content, human-relevant, data.
Parham
Dr Parham Ashrafzadeh is the UK/Nordics Account Manager at CN Bio and is based in London. Parham helps scientists within academia, biotech and pharma sectors to find the best solutions for testing their therapeutics which are more cost effective, clinically relevant and safer at the drug discovery stage. Parham holds a PhD from Uppsala University in Sweden and completed a collaborative postdoctoral fellowship between four universities around the globe.
Raul
Raul Silva is a Scientist working in CN Bio’s Contract Research team. Before joining CN Bio, Raul was a genetic technologist at the Cambridge University Hospitals Genomics Laboratory, working in genetic diagnostic testing. He has a background in genomics and cell biology, having completed a BSc in biomedical science at Anglia Ruskin University and an MSc in cell and gene therapy at University College London. Since joining CN Bio, Raul has had an active role in delivering contract research projects using the PhysioMimix™ OOC microphysiological systems and has become a specialist in CN Bio’s NASH model used to assess anti-NASH compounds efficacy.
Dharaminder
Dr Dharaminder Singh is an experienced Principal Bioengineer, with a background in solving Biological problems using Engineering principles. As an MPS and NAMs advocate he is part of many affiliations working to further the adoption of MPS. Having joined CN Bio in 2017 he worked to help develop the PhysioMimix OOC technology ahead of launch in 2018. Dharaminder has since lead many collaborations including between CN Bio, Vanderbilt University and Astrazeneca, resulting in a PLOS Biology 2022 publication and further development of the technology. Dharaminder now leads the development of OOC consumable plates at CN Bio. Dharaminder graduated from The University of Sheffield with a PhD and MEng in Bioengineering.
Emily
Dr Emily Richardson is a Lead Scientist in the R&D team at CN Bio. She joined the team in 2020 as a Senior Scientist and lead the development of the PhysioMimix lung and lung-liver MPS models. Emily is highly experienced in the application of complex cell biology to drug discovery, having previously worked in cellular therapeutics in an industry setting and as a trained biochemist with specialty in molecular biology. She completed her PhD at the University of Leicester, using 3D cell culture to determine molecular mechanisms driving highly metastatic lung cancers. She now leads R&D projects within the CN Bio team revolving around toxicology in the liver and the lung MPS, as well as driving collaborative projects with various academic, industry and regulatory partners.
Tudor
Dr Tudor Petreus is a senior scientist specializing in biology and MPS system optimization. With a PhD in Medical Sciences and two postdoctoral positions in microfluidics at AstraZeneca UK, together with an extensive experience as an MD consultant and former assistant professor in cell biology, Tudor combines his clinical knowledge with a passion for research and innovation, striving to enhance efficacy, automate processes, and contribute to the advancement of pharmaceutical science.